110 Results
Sort By:
Published on April 5, 2024
Results of the IMvigor011 Phase III trial show that more than 90 percent of muscle invasive bladder cancer patients with a negative circulating tumor DNA (ctDNA) test following surgery, that remained negative at follow up, did not relapse. The results of the trial, presented today at the European Association of…
Published on January 31, 2024
Researchers have known for decades that cisplatin achieves better objective response rates—and can even attain cure—in some patients with bladder cancer better than carboplatin. However, the mechanisms underlying those clinical observations have remained elusive until now. Investigators at the Tisch Cancer Institute at Mount Sinai Medical Center have learned that…
Published on October 25, 2023
Adding immunotherapy to chemotherapy almost doubled survival in patients with an advanced type of bladder cancer, in the first of its kind trial reported in The New England Journal of Medicine and at the annual meeting of the European Society for Medical Oncology (ESMO). The multicenter, international study was co-led by Mount Sinai…
Published on March 15, 2023
Validation testing on the UroAmp test, a urine-based test that detects mutations in 60 genes, was shown to predict bladder cancer up to 12 years before diagnosis. Using two independent cohort studies, researchers from the International Agency for Research on Cancer (IARC) in Lyon, France discovered that urinary comprehensive genomic…
Published on September 14, 2022
Mount Sinai researchers report that they had found a subset of CD8 T cells in bladder cancer that adapt to tumor evasion strategies by appropriating innate-like properties traditionally ascribed to natural killer cells. The finding could offer strategies to overcome the low rates of response to immune checkpoint inhibitor therapies…
Published on August 10, 2022
In the best of circumstances, only 25% of bladder cancers have a durable response following anti-PD-1/PD-L1 immunotherapy. But investigators at the Cedars-Sinai Cancer Center have identified genetic signatures related to the gene discoidin domain receptor tyrosine kinase 2 (DDR2) that may eventually help predict whether tumors in patients with bladder…
Published on May 18, 2022
New longer-term results from the CheckMate 274 trial show that adjuvant immunotherapy with nivolumab after surgery and chemotherapy helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle. This analysis showed that patients treated with immunotherapy…
Published on March 30, 2022
Adding the anti-inflammatory medication celecoxib to immunotherapy and standard chemotherapy drugs appears to suppress aggressive bladder tumor growth, according to a proof-of-concept study led by investigators from Cedars-Sinai Medical Center. The findings, made in laboratory mice, were published in Nature Communications. Chemotherapy and immune checkpoint blockade therapy represent the two pillars…
Published on April 9, 2021
Researchers based at Mount Sinai have identified gene signatures that indicate whether or not someone with metastatic urothelial cancer of the bladder will respond to treatment with immune checkpoint inhibitors or not. As well as identifying genotypes associated with sensitivity and resistance to this therapy, the team also found that…
Published on November 13, 2019
It may be possible to reawaken a patient’s own immune response against a bladder tumor using immunotherapy, according to a recent study by scientists from Barts Cancer Institute in London, Queen Mary University of London, and HistoGeneX in Belgium, which is a laboratory focused on tissue pathology and genomics. Their study was…
Published on August 8, 2019
Liquid biopsy using urine is better than testing blood when it comes to accurately reflecting the genomic profile of bladder cancer tumors. That’s according to a study by researchers in Japan that found that identification of tumor-identical mutations was an order of magnitude better using urine versus blood plasma. The…
Published on July 31, 2017
Sponsor: MDx Health MDxHealth has launched its AssureMD for Bladder Cancer test in the United States as a laboratory developed test (LDT). Testing will be conducted at the company’s CAP and CLIA accredited laboratory facilities in Irvine, CA. AssureMDx is a noninvasive, urine-based test, combining methylation and mutation biomarkers, to…
Published on July 7, 2017
A newly-developed urine biomarker test can not only detect low-grade urothelial bladder cancer (UBC), but predict the likelihood of its recurrence earlier and more accurately than current cytology methods, according to a study released yesterday. Françoise Descotes, Ph.D., Alain Ruffion, M.D., Ph.D., and colleagues at the University Hospital of Lyon…
Published on June 20, 2016
New research aimed at mapping the molecular mechanisms behind the early stages of bladder cancer has discovered that tumors of the disease can be divided into three primary classes, each with very different molecular and disease developing characteristics. The study's findings—presented by a team of researchers from Aarhus University in…
Published on June 9, 2016
Scientists at the University of Colorado Cancer Center say they used next-generation sequencing technologies to perform the most detailed DNA-based analysis to date of 25 commonly used bladder cancer cell lines. The work allowed the team to match patient tumors with their closest genetic cell line match and demonstrated genetic…